If you plan to continue training seriously while using these medications, nutrition cannot be left entirely to appetite cues
"For retatrutide, the findings from TRIUMPH-4 are encouraging, and with seven additional phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis," a Lilly spokesperson said in a statement to Fox News Digital
Do not double the dose to "catch up." Mistake 4: Comparing milligrams across peptides A user on semaglutide 2.4 mg who switches to tirzepatide should not start at 2.5 mg thinking it is "about the same." While 2.5 mg happens to be the tirzepatide starting dose, the reasoning should be based on escalation protocol, not milligram matching
It is a commitment to improved well-being
Alfaris said gastrointestinal adverse events were more common with orforglipron than placebo and were consistent with those seen in other incretin-based drugs